Release Date: December 21, 2020
Expiration Date: December 21, 2021

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The impact of COVID-19 on the routine management of patients with sickle cell disease (SCD) has been substantial and complex, as clinicians now need to ensure that patients receive appropriate care for SCD in balance with the challenges posed by the pandemic. In this article, Lanetta Bronté-Hall, MD, MPH, MSPH discusses the current data regarding the prevalence of COVID-19 among patients with SCD and provides guidance on best practice on the treatment and monitoring of SCD during the COVID-19 pandemic.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with sickle cell disease.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Discuss acute and chronic disease management in African Americans with SCD during COVID-19

Agenda

African Americans, Sickle Cell Disease, and COVID-19: Dispelling Myths and Addressing Facts - Lanetta Bronté-Hall, MD, MPH, MSPH

Instructions for Participation and Credit

This activity is eligible for credit through December 21, 2021. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Lanetta Bronté-Hall, MD, MPH, MSPH
President
Foundation for Sickle Cell Disease Research
Hollywood, Florida

Dr. Lanetta Bronté-Hall received a joint medical degree and master of public health with a specialization in health policy and administration from the University of North Carolina School of Medicine and Gillings School of Global Public Health. She completed an internship in internal medicine at Tulane University School of Medicine, and a residency in psychiatry at the University of Miami, Miller School of Medicine. In addition, she completed a health research and educational trust/American Hospital Association fellowship in cultural competence and leadership. Dr. Bronté-Hall is currently President and CEO of the Foundation for Sickle Cell Disease Research (FSCDR), where she is responsible for strategic planning, scientific, and administrative oversight. In addition, she is Chief Health Officer of the Sickle Care and Research Network, FSCDR, LLC, an independent full-service outpatient medical treatment and clinical trials center that offers medical and coordinated care for underserved populations. Dr. Bronté-Hall is also an Associate Professor in the Department of Public Health Sciences, Department of Health Services Research and Policy at the University of Miami’s Miller School of Medicine, where she has created a sickle cell disease research portfolio and an academic–community partnership to translate research into practice.

Dr. Bronté-Hall has served in several leadership positions including the Chief Medical Officer of the Sickle Cell Disease Association of America, Senior Medical Advisor to the Centers for Disease Prevention and Control, and as a member of the National Institutes of Health, National Heart, Lung and Blood Advisory Council. A leading national and international researcher and population health scientist in the field of sickle cell disease, rare blood disorders, community-based participatory research, and chronic disease management, Dr. Bronté-Hall has extensive experience in developing programs that are closely aligned with the recruitment and retention of underserved and underrepresented populations for treatment of sickle cell disease and breast cancer research and clinical trials. She has spearheaded a Sickle Cell Disease and Thalassemia Registry. Dr. Bronté-Hall works tirelessly to create an environment of trust, sustainability and relevance, which has significantly increased participation in research by all members of the community.

Accreditation

CME CREDIT Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: MediCom Worldwide, Inc. designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-044-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Lanetta Bronté-Hall has disclosed no relevant financial relationships.

Dr. Haifa Kassis, Medical Writer, has no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Global Blood Therapeutics.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.